
    
      The Sabin IPV was manufactured with poliovirus type1, 2, 3 Sabin strains and Vero cells by
      microcarrier culture in 550 liter bioreactors. The virus suspension was harvested
      ,ultra-concentrated, purified and inactivated with formalin. Three formulations A,B,C of
      Sabin IPV were used, the DAg contents for A were type1 45,type2 64,type3 67.5 DU /0.5ml/per
      dose; for B 30,32,45 DU/0.5ml/per dose; for C 15,16,22.5 DU/0.5ml/per dose.

      Oral Poliomyelitis Vaccine(OPV)was manufactured by Institute of Medical Biology, Chinese
      Academy of Medical Sciences.Trivalent OPV contains Polioviruses Type 1 6.0 log CCID Type 2
      5.0 log Type 3 5.5log /0.1ml/per dose Inactivated Poliomyelitis Vaccine (Salk strains)was
      manufactured by Sanofi Pasteur DAg contents /0.5ml/per dose were Type 1 40 DU,Type 2 8DU,Type
      3 32DU.

      This is a randomized, blind phase 2 clinical trial. Total 500 infants (ages 60 days to 90
      days) were selected , randomized to five groups(each group n=100) Sabin IPV formulations
      A,B,C,OPV ,Salk IPV were separately given to each group with three doses one month apart
      respectively.
    
  